Gapping up
In reaction to earnings/guidance:
- TIGR +6.9%, MMYT +5.3%, NDSN +4.2%, CRMT +4.1%, ARCE +2.7%
Other news:
- TLC +12.1% (receives approval of NDA of Liposomal Amphotericin B in India)
- JYNT +10.8% (to be added to the S&P SmallCap 600)
- PSTI +8.9% (to receive EUR20 mln in non-dilutive funding from the EIB)
- SRRK +8.3% (apitegromab granted Fast Track designation for Spinal Muscular Atrophy)
- TGTX +6.8% (FDA has accepted the Biologics License Application for ublituximab in combination with UKONIQ)
- TLSA +5.6% (initiates clinical trial in a secondary progressive multiple sclerosis patient)
- GSMG +4.1% (commences the commercial applications of its blockchain and NFT technologies through its digital copyright management platform)
- HYFM +3.3% (to acquire House & Garden)
- YTRA +2.4% (stock offering and mixed shelf offering)
- OCN +2.1% (to acquire $48 bln in bulk servicing rights from AmeriHome Mortgage)
- LAD +1.8% (announces the acquisition of three Hyundai dealerships in LV)
- CONE +1.6% (names new Chair of Board)
- ONEM +1.5% (reports that a longitudinal study finds that its primary care model delivers outsized impact in controlling diabetes)
- FSR +1.5% (selects ServiceNow (NOW) solutions to accelerate electric vehicle product development)
- AUTL +1.4% (announces an additional nature publication for AUTO1)
- UAL +1.4% (has experienced an acceleration in ticketed yields for the second quarter, ahead of previous expectations)
- ATSG +1.1% (announces lease with DHL to provide four additional Boeing 767 freighters)
- BA +1.1% (receives order for 14 Boeing 737 MAX Jets from SMBC Aviation Capital)
Analyst comments:
- SHAK +5.5% (upgraded to Buy from Neutral at Goldman)
- CGC +4% (upgraded to Buy from Neutral at MKM Partners)
- TELL +3.3% (upgraded to Buy from Hold at DNB Markets)
- DK +2.7% (upgraded to Overweight from Neutral at Piper Sandler)
- DHT +2.6% (upgraded to Outperform from In-line at Evercore ISI)
- APPN +2.3% (upgraded to Neutral from Underperform at Macquarie)